Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the central nervous system (CNS).

Our first-generation compound, rapastinel (GLYX-13), is in development as adjunctive therapy for patients who are unable to achieve an adequate response to other anti-depressants. Rapastinel (GLYX-13) has shown rapid-acting and robust antidepressant activity in Phase 2 clinical studies and has been well-tolerated with none of the psychotomimetic side effects that limit other drugs  targeting the NMDA receptor. Naurex’s second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.

These lead programs stem from the company’s proprietary platform for discovering compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with synaptic plasticity. This mechanism has therapeutic potential in a number of CNS diseases with high unmet medical needs.